NCT02189343 - Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

April 18, 2018

Study Completion Date

April 30, 2018

Conditions

Multiple Myeloma

Interventions

DRUG

ACY-1215 in combination with pomalidomide and dexamethasone

Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.

Trial Locations (3)

CTRC at The UT Health Science Center at San Antonio, San Antonio

University of Utah Huntsman Cancer Institute, Salt Lake City

UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas